Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

References

• Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44(12):2027–2032.
   PubMed Web of Science ®Google Scholar
• Bitter EE, Townsend MH, Erickson R, et al. Thymidine kinase 1 through the ages: a comprehensive review. Cell Biosci. 2020;10(1):138.
   PubMed Web of Science ®Google Scholar
• Bagegni N, Thomas S, Liu N, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 2017;19(1):123.
   PubMed Web of Science ®Google Scholar
• McCartney A, Bonechi M, De Luca F, et al. Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial. Clin Cancer Res. 2020;26(9):2131–2139.
   PubMed Web of Science ®Google Scholar
• Cabel L, Rosenblum D, Lerebours F, et al. Plasma thymidine kinase 1 activity and outcome of ER + HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res. 2020;22(1):98.
   PubMed Web of Science ®Google Scholar
• Felix K, Hinz U, Dobiasch S, et al. Preoperative serum thymidine kinase activity as novel monitoring, prognostic, and predictive biomarker in pancreatic cancer. Pancreas. 2018;47(1):72–79.
   PubMed Web of Science ®Google Scholar
• McCartney A, Biagioni C, Schiavon G, et al. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III evaluation of faslodex versus exemestane clinical trial (EFECT). Eur J Cancer. 2019;114:55–66.
   PubMed Web of Science ®Google Scholar
• Nisman B, Appelbaum L, Yutkin V, et al. Serum thymidine kinase 1 activity Following nephrectomy for renal cell carcinoma and radiofrequency ablation of metastases to lung and liver. Anticancer Res. 2016;36(4):1791–1797.
   PubMed Web of Science ®Google Scholar
• Nisman B, Nechushtan H, Biran H, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014;9(10):1568–1572.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform, et al. Melanoma staging: Evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Costa Svedman F, Jalsenius M, Hoiom V, et al. Plasma thymidine kinase activity as a novel biomarker in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancers (Basel). 2022;14(3):702.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Ma J, et al. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Anticancer Res. 2010;30(4):1295–1299.
   PubMed Web of Science ®Google Scholar
• Larsson AM, Bendahl PO, Aaltonen K, et al. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Sci Rep. 2020;10(1):4484.
   PubMed Web of Science ®Google Scholar